Literature DB >> 12388741

Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype.

Roberto Burioni1, Yoshiharu Matsuura, Nicasio Mancini, Hideki Tani, Tatsuo Miyamura, Pietro E Varaldo, Massimo Clementi.   

Abstract

Hepatitis C virus (HCV) is the major causative agent of blood-borne non-A, non-B hepatitis. Although a strong humoral response is detectable within a few weeks of primary infection and during viral persistence, the role played by antibodies against HCV envelope glycoproteins in controlling viral replication is still unclear. We describe how human monoclonal anti-HCV E2 antibody fragments isolated from a chronically HCV-infected patient differ sharply in their abilities to neutralize infection of HepG2 cells by a vesicular stomatitis virus pseudotype bearing HCV envelope glycoproteins. Two clones were able to neutralize the pseudotype virus at a concentration of 10 micro g/ml, while three other clones completely lacked this activity. These data can explain the lack of protection and the possibility of reinfection that occur even in the presence of a strong antiviral antibody response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388741      PMCID: PMC136746          DOI: 10.1128/jvi.76.22.11775-11779.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  A novel expression vector for production of epitope-tagged recombinant Fab fragments in bacteria.

Authors:  R Burioni; F Bugli; N Mancini; G Fadda
Journal:  Hum Antibodies       Date:  2001

2.  Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries.

Authors:  F Bugli; N Mancini; C Y Kang; C Di Campli; A Grieco; A Manzin; A Gabrielli; A Gasbarrini; G Fadda; P E Varaldo; M Clementi; R Burioni
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Cell fusion activity of hepatitis C virus envelope proteins.

Authors:  S Takikawa; K Ishii; H Aizaki; T Suzuki; H Asakura; Y Matsuura; T Miyamura
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Murine humoral immune response against recombinant structural proteins of hepatitis C virus distinct from those of patients.

Authors:  M Ahmed; T Shikata; M Esumi
Journal:  Microbiol Immunol       Date:  1996       Impact factor: 1.955

5.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

Authors:  D Rosa; S Campagnoli; C Moretto; E Guenzi; L Cousens; M Chin; C Dong; A J Weiner; J Y Lau; Q L Choo; D Chien; P Pileri; M Houghton; S Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 6.  Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

Authors:  A Cerny; F V Chisari
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

7.  Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia.

Authors:  R Lesniewski; G Okasinski; R Carrick; C Van Sant; S Desai; R Johnson; J Scheffel; B Moore; I Mushahwar
Journal:  J Med Virol       Date:  1995-04       Impact factor: 2.327

8.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases.

Authors:  H Ohashi; K Maruyama; Y C Liu; A Yoshimura
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

View more
  13 in total

1.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

2.  Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening.

Authors:  Jennifer M Pfaff-Kilgore; Edgar Davidson; Kathryn Kadash-Edmondson; Mayda Hernandez; Erin Rosenberg; Ross Chambers; Matteo Castelli; Nicola Clementi; Nicasio Mancini; Justin R Bailey; James E Crowe; Mansun Law; Benjamin J Doranz
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

3.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

Review 4.  Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.

Authors:  Giuseppe Sautto; Nicasio Mancini; Giacomo Gorini; Massimo Clementi; Roberto Burioni
Journal:  Biomed Res Int       Date:  2013-08-22       Impact factor: 3.411

5.  Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.

Authors:  Hideki Tani; Yasumasa Komoda; Eiko Matsuo; Kensuke Suzuki; Itsuki Hamamoto; Tetsuo Yamashita; Kohji Moriishi; Kazuhito Fujiyama; Tatsuya Kanto; Norio Hayashi; Ania Owsianka; Arvind H Patel; Michael A Whitt; Yoshiharu Matsuura
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 6.  Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens.

Authors:  Nicola Clementi; Nicasio Mancini; Laura Solforosi; Matteo Castelli; Massimo Clementi; Roberto Burioni
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208

Review 7.  Multiantibody strategies for HIV.

Authors:  Andrew Hiatt; Larry Zeitlin; Kevin J Whaley
Journal:  Clin Dev Immunol       Date:  2013-06-06

Review 8.  Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).

Authors:  Giuseppe Sautto; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

Review 9.  Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?

Authors:  Mancini Nicasio; Giuseppe Sautto; Nicola Clementi; Roberta A Diotti; Elena Criscuolo; Matteo Castelli; Laura Solforosi; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

Review 10.  JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?

Authors:  Roberta Antonia Diotti; Akira Nakanishi; Nicola Clementi; Nicasio Mancini; Elena Criscuolo; Laura Solforosi; Massimo Clementi
Journal:  Clin Dev Immunol       Date:  2013-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.